Indeed, mice bearing non-functional TLR9 or MyD88, or treated with a TLR7/TLR9 antagonist display a less pronounced inflammatory response and attenuated pathology during experimental malaria [23], [26], [38], [41]. Here, MYD88 is linked to malaria.